Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619433 | 0.83 | PIK3CG (0.41) | CDK2PIK3CG | |
| SCHEMBL25065960 | 0.82 | PIK3CG (0.38) | PIK3CG | |
| SCHEMBL9135636 | 0.74 | LRRK2 (0.36) | — | |
| SCHEMBL20858065 | 0.74 | CDK2 (0.34) | CDK2 | |
| SCHEMBL21720481 | 0.71 | CDK2 (0.34) | CDK2 | |
| SCHEMBL16022256 | 0.71 | HDAC6 (0.33) | — | |
| SCHEMBL22314881 | 0.71 | CDK2 (0.39) | CDK2PIK3CG | |
| SCHEMBL22652947 | 0.70 | CA2 (0.31) | — | |
| SCHEMBL25604154 | 0.70 | — | — | |
| SCHEMBL2616422 | 0.69 | CDK2 (0.35) | CDK2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
| EP-3611165-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20200045968-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUI CHEMICALS AGRO, INC. (JP) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CDK2 4475/4885PIK3CG 3077/4885 |
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | CDK2 4653/4885PIK3CG 1947/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | CDK2 3642/4885PIK3CG 3992/4885 |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | PNPO, CYP4X1, PDXK | CDK2 580/4885PIK3CG 1328/4885 |
| US-20200045968-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | PNPO, CYP4X1, PDXK | CDK2 580/4885PIK3CG 1328/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | CDK2 4653/4885PIK3CG 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.